Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design,synthesis, and X-ray cocrystal structure |
| |
Authors: | Canan Koch Stacie S Thoresen Lars H Tikhe Jayashree G Maegley Karen A Almassy Robert J Li Jianke Yu Xiao-Hong Zook Scott E Kumpf Robert A Zhang Cathy Boritzki Theodore J Mansour Rena N Zhang Kanyin E Ekker Anne Calabrese Chris R Curtin Nicola J Kyle Suzanne Thomas Huw D Wang Lan-Zhen Calvert A Hilary Golding Bernard T Griffin Roger J Newell David R Webber Stephen E Hostomsky Zdenek |
| |
Affiliation: | Pfizer Global Research and Development, La Jolla/Agouron Pharmaceuticals, Inc., 10770 Science Center Drive, San Diego, California 92121, USA. stacie.canan@pfizer.com |
| |
Abstract: | A series of novel compounds have been designed that are potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1), and the activity and physical properties have been characterized. The new structural classes, 3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-6-ones and 3,4-dihydropyrrolo[4,3,2-de]isoquinolin-5-(1H)-ones, have conformationally locked benzamide cores that specifically interact with the PARP-1 protein. The compounds have been evaluated with in vitro cellular assays that measure the ability of the PARP-1 inhibitors to enhance the effect of cytotoxic agents against cancer cell lines. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|